Therapy Areas: Vaccines
KalVista Pharmaceuticals Names Soland to Board of Directors
23 April 2019 - - US-based stage pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has appointed Daniel Soland to its board of directors effective immediately, the company said.

Soland most recently served as the chief executive officer of uniQure N.V. and senior vice president and chief operating officer of ViroPharma.

In addition to his most recent positions, Soland has an extensive background in the pharmaceutical industry.

He currently serves on the boards of directors of Acadia Pharmaceuticals and DBV Technologies. Soland served as president of Chiron Vaccines until the acquisition of Chiron by Novartis.

Prior to that, he was president and chief executive officer of Epigenesis Pharmaceuticals and earlier was vice president and director, Worldwide Marketing Operations for GlaxoSmithKline Biologicals.

Earlier in his career, Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux's Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa.

KalVista Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialisation of small molecule protease inhibitors.

The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body's inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation.

KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema and diabetic macular edema.

The company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for HAE as well as DME.

The company has selected KVD900 as its programme to be advanced as an on-demand therapy for HAE attacks and commenced a Phase 2 proof-of-concept study in HAE patients in late 2018.

In DME, KalVista's most advanced program, an intravitreally administered plasma kallikrein inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that is anticipated to complete in the second half of 2019.
Login
Username:

Password: